Results 101 to 110 of about 8,893 (235)

Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review

Journal of Translational Medicine
Background Glucagon-like peptide-1 receptor agonist (GLP-1RAs) is a potent therapy for type 2 diabetes mellitus (T2DM) and obesity, especially in patients who are resistant to long-term insulin therapy.
Haifeng Yu, Maryam Davoudi, Sahar Sadegh-Nejadi, Xiaolei Miao, Molood Bagherieh, Reza Afrisham   +5 more
doaj   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1984-1996, March 2026.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis [PDF]

, 2019
GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) have been associated with improved glycemic control, body weight loss and favorable changes in cardiovascular risk factors and outcomes. We conducted a systematic review and meta-analysis to
Brescia F., Castellana M., Cignarelli A., Giorgino F., Laviola L., Natalicchio A., Perrini S.   +6 more
core   +1 more source

Effects of GLP‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

International Journal of Dermatology, EarlyView.
Miranda K. Branyiczky, Megan S. Lowe, Eric McMullen, Jeffrey Donovan, Touraj Khosravi‐Hafshejani   +4 more
wiley   +1 more source

Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1622-1637, March 2026.
Abstract Neurodegenerative diseases, including debilitating conditions like Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, a process fundamentally driven by persistent chronic neuroinflammation and central metabolic dysfunction.
Renata Spezani, Carlos A. Mandarim‐de‐Lacerda   +1 more
wiley   +1 more source

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial [PDF]

, 2016
Background: Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk.
A Collier, A Goyal, A Ludman, A. Comlekci, AE Sumner, American Diabetes Association, American Diabetes Association, BA Swinburn, BM Scirica, C Daousi, CJ Lavie, CJ Li, D Wormser, E Selvin, E. Franek, EA Molenaar, Expert Panel on Detection, F. M. M. Baeres, I Chopra, I. Raz, ID Caterson, IM Rückert, J Logue, J. Petrie, J. Vidal, JB Albu, K Niswender, KG Alberti, L Blonde, L Guenette, L. A. Leiter, L. Masmiquel, L. van Gaal, LA Vázquez, LG Goh, LN McEwen, M Bastien, M Leenders, M Ng, M. Eriksson, MA Bethel, MD Jensen, ME Farkouh, MJ Davies, NJ Stone, NR Jones, P Li, P Weeke, RR Wing, S Baxi, S. Bain, S. Jacob, S. P. Marso, SK Paul, SP Marso, T Tillin, The Emerging Risk Factors Collaboration, UE Ntuk, V Bhan, X Pi-Sunyer   +59 more
core   +2 more sources

Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2183-2202, March 2026.
Abstract Aims The extent to which the cardiovascular benefits of sodium–glucose co‐transporter 2 inhibitors (SGLT‐2is) and glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) differ by sex remains unclear. This systematic meta‐analysis aimed to investigate sex differences in trial representation and the cardiovascular and kidney efficacy of SGLT‐2is ...
Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor K. Kunutsor   +6 more
wiley   +1 more source

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.

, 2017
AIM: To investigate the mechanism of action for body weight loss with semaglutide. MATERIALS AND METHODS: This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks treatment with once-weekly ...
Axelsen, MB, Blundell, J, Finlayson, G, Flint, A, Gibbons, C, Hjerpsted, J, Kvist, T   +6 more
core   +1 more source

GLP‐1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study

BJUI Compass, Volume 7, Issue 2, February 2026.
Abstract Objectives The purpose of this study is to investigate the impact of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) use on 90‐day postoperative outcomes and overall survival following partial nephrectomy (PN) for renal cell carcinoma (RCC), where type 2 diabetes mellitus (T2DM) is a common comorbidity.
Sam Kwon, Fiona Wardrop, Diego Gonzalez, Francis Ryan, Liza Khutsishvili, Rollins Turner, Mohammad Ghassab Deameh, Michael J. Whalen   +7 more
wiley   +1 more source

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers ...
Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J. S. Coats, Dike Ojji, Adriana Puente Barragán, Peter Rossing, Shelley Zieroth, Shaaf Ahmad, Shariq Usman, Geeta Appannah, Alison L. Bailey, Ahmed Bennis, Andrea Brandao, Javed Butler, Melanie J. Davies, Lubomira Fabryova, Yuan‐Lin Guo, Hidetaka Itoh, Uday M. Jadhav, Carel W. Le Roux, Fausto J. Pinto, Julio Rosenstock, Banshi Saboo, Hani Sabbour, Mangesh Tiwaskar, Karol E. Watson, Kwang Wei Tham, Fernando Stuardo Wyss, Walter P. Abhayaratna, William T. Abraham, Wael Al Mahmeed, Alessia Argirò, John J. Atherton, Danielle Belardo, Raquel Campuzano, Nandini Chatterjee, Marc‐André Cornier, Sarah Davies, Clemencia de Rueda Panadero, Anastase Dzudie, Ty J. Gluckman, Muhammad Shahzeb Khan, Kamlesh Khunti, Yuri Lopatin, Zhiyi Ma, Okechukwu S. Ogah, Abraham Oomman, Emilio S. Peralta Lopez, Ping Li, Paul Poirier, Julie Redfern, Giuseppe M. C. Rosano, Donna Ryan, Amit Saraf, Sameh Shaheen, Subodh Verma, Stephan von Haehling, Martha Gulati, Naveed Sattar, Jose Luis Zamorano   +60 more
wiley   +1 more source